Press-release for stocks related to pharm-country for PFE

Prices are updated after-hours

tags : Pharm-country symbols : PFE

save search

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| 1.23% | O: 0.0% H: 1.92% C: 1.0%
emblaveo treatment for infections

Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| 0.0% | O: 0.11% H: 0.38% C: -0.04%
meeting

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -0.88% | O: 0.73% H: 2.49% C: 0.11%
abrysvo disease positive risk for rsv results study

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - March 5, 2024
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| 1.66% | O: -0.08% H: 2.13% C: 0.81%
conference

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -5.19% | O: -0.32% H: 0.0% C: -1.77%
TNXP | $0.1574 1.29% 1.27% 1.6M

Health Technology

| -50.31% | O: 4.32% H: 7.17% C: 2.5%
drug fibromyalgia study

European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
Published: 2024-02-19 (Crawled : 17:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| Email alert Add to watchlist
velsipity active

European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
Published: 2024-01-08 (Crawled : 18:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -10.69% | O: -0.37% H: 1.09% C: 0.75%
talzenna cancer

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - September 19, 2023
Published: 2023-09-19 (Crawled : 14:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -21.76% | O: -0.27% H: 1.37% C: 1.31%
conference

Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27
Published: 2023-04-13 (Crawled : 16:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -36.38% | O: 0.39% H: 0.41% C: -0.14%
meeting

Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma
Published: 2023-04-03 (Crawled : 18:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -35.49% | O: -0.27% H: 1.91% C: 1.62%
show

Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
Published: 2023-02-28 (Crawled : 00:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -35.46% | O: -0.69% H: 0.52% C: 0.17%
fda candidate vaccine rsv approval potential positive

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
Published: 2023-01-06 (Crawled : 17:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -47.0% | O: 0.64% H: 3.24% C: 1.88%
fda children vaccine application license review pneumococcal

U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
Published: 2022-12-07 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -47.05% | O: 0.08% H: 2.81% C: 0.98%
fda candidate disease vaccine application respiratory license virus review

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - November 28, 2022
Published: 2022-11-28 (Crawled : 16:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -46.51% | O: -0.06% H: 1.14% C: 0.79%
conference

Pfizer Completes Acquisition of Global Blood Therapeutics
Published: 2022-10-05 (Crawled : 16:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -40.8% | O: -0.76% H: 0.57% C: 0.0%
acquisition blood global therapeutics

Pfizer Declares Fourth-Quarter 2022 Dividend
Published: 2022-09-22 (Crawled : 13:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -40.07% | O: -0.57% H: 3.05% C: 2.06%

Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries
Published: 2022-09-22 (Crawled : 11:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -40.07% | O: -0.57% H: 3.05% C: 2.06%
treatment global

Oligomerix Announces Key Organizational Changes in Transition to Clinically Focused Company
Published: 2022-07-20 (Crawled : 13:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -48.76% | O: 0.04% H: 0.14% C: -1.11%

Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
Published: 2022-03-29 (Crawled : 18:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology

| -50.6% | O: 1.35% H: 0.15% C: -2.33%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -7.2% | O: -0.12% H: 0.0% C: 0.0%
BNTX | News | $88.53 0.59% 0.59% 360K

Health Technology

| -46.8% | O: 1.83% H: 3.58% C: 1.77%
covid-19 authorization vaccine order emergency use authorization

Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Published: 2022-02-25 (Crawled : 13:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M

Health Technology